Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $2.22B | $2.19B | +1.37% |
Cost of Revenue | $622M | $643M | -3.27% |
Net Income | $631M | $599M | +5.34% |
EPS (Basic) | $1.41 | $1.31 | +7.63% |
EPS (Diluted) | $1.41 | $1.31 | +7.63% |
SG&A Expense | $563M | $547M | +2.93% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $14.1B | $14.35B | -1.74% |
Current Assets | $5.88B | $6.36B | -7.58% |
Total Liabilities | $9.44B | $9.3B | +1.58% |
Current Liabilities | $3.38B | $1.91B | +77.32% |
Stockholders' Equity | $4.66B | $5.06B | -7.97% |
Cash & Equivalents | $1.72B | $1.98B | -12.86% |
Long-Term Debt | $5.23B | $6.56B | -20.34% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $587M | $595M | -1.34% |
Investing Cash Flow | $-175M | $-131M | -33.59% |
Financing Cash Flow | $-677M | $-524M | -29.20% |
Share Buybacks | $443M | $339M | +30.68% |
D&A | $119M | $126M | -5.56% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 28.4% | — | — |
ROE | 13.6% | — | — |
ROA | 4.5% | — | — |
Current Ratio | $1.736 | — | — |
Debt to Equity | $2.029 | — | — |
Other companies in Pharmaceuticals